| The current stage of cathepsin B inhibitors as potential anticancer agents J Kos, A Mitrović, B Mirković Future medicinal chemistry 6 (11), 1355-1371, 2014 | 124 | 2014 |
| A road map for prioritizing warheads for cysteine targeting covalent inhibitors P Abranyi-Balogh, L Petri, T Imre, P Szijj, A Scarpino, M Hrast, A Mitrović, ... European journal of medicinal chemistry 160, 94-107, 2018 | 120 | 2018 |
| The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors A Pišlar, A Mitrović, J Sabotič, U Pečar Fonović, M Perišić Nanut, T Jakoš, ... PLoS pathogens 16 (11), e1009013, 2020 | 95 | 2020 |
| Cystatins in cancer progression: More than just cathepsin inhibitors B Breznik, A Mitrović, TT Lah, J Kos Biochimie 166, 233-250, 2019 | 88 | 2019 |
| Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity B Mirković, B Markelc, M Butinar, A Mitrović, I Sosič, S Gobec, O Vasiljeva, ... Oncotarget 6 (22), 19027, 2015 | 68 | 2015 |
| Clioquinol–ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity A Mitrović, J Kljun, I Sosič, S Gobec, I Turel, J Kos Dalton Transactions 45 (42), 16913-16921, 2016 | 50 | 2016 |
| Cysteine cathepsins B and X promote epithelial-mesenchymal transition of tumor cells A Mitrović, UP Fonović, J Kos European journal of cell biology 96 (6), 622-631, 2017 | 47 | 2017 |
| Inhibition of endopeptidase and exopeptidase activity of cathepsin B impairs extracellular matrix degradation and tumour invasion A Mitrović, B Mirković, I Sosič, S Gobec, J Kos Biological chemistry 397 (2), 165-174, 2016 | 41 | 2016 |
| Cathepsin B inhibitors: Further exploration of the nitroxoline core I Sosič, A Mitrović, H Ćurić, D Knez, HB Žugelj, B Štefane, J Kos, S Gobec Bioorganic & medicinal chemistry letters 28 (7), 1239-1247, 2018 | 37 | 2018 |
| Nitroxoline: repurposing its antimicrobial to antitumor application A Mitrović, J Kos Acta Biochimica Polonica 66 (4), 521-531, 2019 | 25 | 2019 |
| Identification and characterization of the novel reversible and selective cathepsin X inhibitors UP Fonović, A Mitrović, D Knez, T Jakoš, A Pišlar, B Brus, B Doljak, ... Scientific reports 7 (1), 11459, 2017 | 22 | 2017 |
| Addition of 2-(ethylamino) acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo A Mitrović, I Sosič, Š Kos, UL Tratar, B Breznik, S Kranjc, B Mirković, ... Oncotarget 8 (35), 59136, 2017 | 19 | 2017 |
| Lysosomal peptidases—intriguing roles in cancer progression and neurodegeneration J Kos, A Mitrović, M Perišić Nanut, A Pišlar FEBS Open Bio 12 (4), 708-738, 2022 | 18 | 2022 |
| Natural apocarotenoids and their synthetic glycopeptide conjugates inhibit SARS-CoV-2 replication I Bereczki, H Papp, A Kuczmog, M Madai, V Nagy, A Agócs, G Batta, ... Pharmaceuticals 14 (11), 1111, 2021 | 11 | 2021 |
| Cystatin F acts as a mediator of immune suppression in glioblastoma E Senjor, M Perišić Nanut, B Breznik, A Mitrović, J Mlakar, A Rotter, ... Cellular Oncology 44 (5), 1051-1063, 2021 | 11 | 2021 |
| 8-Hydroxyquinoline-based anti-Alzheimer multimodal agents D Knez, I Sosič, A Mitrović, A Pišlar, J Kos, S Gobec Monatshefte für Chemie-Chemical Monthly 151, 1111-1120, 2020 | 10 | 2020 |
| Evaluation of novel cathepsin-X inhibitors in vitro and in vivo and their ability to improve cathepsin-B-directed antitumor therapy A Mitrović, J Završnik, G Mikhaylov, D Knez, U Pečar Fonović, ... Cellular and Molecular Life Sciences 79 (1), 34, 2022 | 9 | 2022 |
| Targeting of fluorescent Lactococcus lactis to colorectal cancer cells through surface display of tumour‐antigen binding proteins TV Plavec, A Mitrović, M Perišić Nanut, B Štrukelj, J Kos, A Berlec Microbial Biotechnology 14 (5), 2227-2240, 2021 | 9 | 2021 |
| Biological evaluation of 8-hydroxyquinolines as multi-target directed ligands for treating Alzheimer’s disease D Knez, I Sosič, A Pišlar, A Mitrović, M Jukič, J Kos, S Gobec Current Alzheimer Research 16 (9), 801-814, 2019 | 8 | 2019 |
| Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria I Bereczki, V Vimberg, E Lőrincz, H Papp, L Nagy, S Kéki, G Batta, ... Scientific reports 12 (1), 16001, 2022 | 7 | 2022 |
